



## KIDNEY CANCER SUPPORT NETWORK

Website: [www.kcsn.org.uk](http://www.kcsn.org.uk)

Email: [team@kcsn.org.uk](mailto:team@kcsn.org.uk)

Office: 01209 891 307

Helpline: 01209 890 326



### Access to Kidney Cancer Treatments in the UK – 14 December 2020

Trade name <i>Manufacturer</i>	Generic name	How it works	Indication	Availability
<b>First-line treatments</b>				
<b>Bavencio</b> plus <b>Inlyta</b> <i>Merck/Pfizer</i>	Avelumab in combination with axitinib	<b>Immunotherapy plus targeted therapy:</b> Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion plus oral medication	First-line treatment for advanced/metastatic RCC	Available via the Cancer Drugs Fund (CDF) for patients in England and Wales. Available on the NHS in Scotland
<b>Keytruda</b> plus <b>Inlyta</b> <i>MSD/Pfizer</i>	Pembrolizumab in combination with axitinib	<b>Immunotherapy plus targeted therapy:</b> Anti-PD-1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion plus oral medication	First-line treatment for advanced RCC	Available on the NHS in Scotland. Not available on the NHS in England and Wales
<b>Opdivo</b> plus <b>Yervoy</b> <i>BMS</i>	Nivolumab in combination with ipilimumab	<b>Immunotherapy:</b> Anti-PD1 checkpoint inhibitor plus anti-CTLA4 inhibitor Infusion	First-line treatment for intermediate and poor risk advanced RCC	Available via the Cancer Drugs Fund (CDF) to patients in England Available on the NHS in Scotland
<b>Sutent</b> <i>Pfizer</i>	Sunitinib	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
<b>Votrient</b> <i>Novartis</i>	Pazopanib	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
<b>Cabometyx</b> <i>Ipsen</i>	Cabozantinib	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for locally advanced/metastatic RCC	Available on the NHS

A patient-led Kidney Cancer Support Network established in 2006

Registered Charity No: **1164238** The Bungalow, West Cliff, Porthtowan, Cornwall, TR4 8AE

<b>Fotivda</b> <i>Aveo/Eusa</i>	Tivozanib	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
<b>Second-line treatments</b>				
<b>Kisplyx plus Afinitor</b> <i>Eisai, Novartis</i>	Lenvatinib in combination with everolimus	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) plus mTOR inhibitor Oral medication	Second-line treatment for advanced RCC	Available on the NHS
<b>Inlyta</b> <i>Pfizer</i>	Axitinib	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Oral medication	Second-line treatment for advanced RCC	Available on the NHS
<b>Second line and beyond treatments</b>				
<b>Opdivo</b> <i>BMS</i>	Nivolumab	<b>Immunotherapy:</b> Anti-PD1 checkpoint inhibitor	Second/third-line treatment for advanced/metastatic RCC	Available on the NHS
<b>Cabometyx</b> <i>Ipsen</i>	Cabozantinib	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Oral medication	Second/third-line treatment for advanced RCC after VEGF-TKI treatment	Available on the NHS
<b>Afinitor</b> <i>Novartis</i>	Everolimus	<b>Targeted therapy:</b> mTOR inhibitor Oral medication	Second/third-line treatment for advanced RCC	Available on the NHS in England, Scotland and Wales
<b>Other treatments for advanced kidney cancer</b>				
<b>Intron A/Roferon A</b> <i>MSD</i>	Interferon	<b>Immunotherapy:</b> Cytokine Infusion	Advanced/metastatic RCC	Available on the NHS
<b>Proleukin</b> <i>Clinigen</i>	Interleukin 2 (IL 2)	<b>Immunotherapy:</b> Cytokine Infusion	Advanced/metastatic RCC	Available to pre-selected patients only at specialist research sites (Christie Hospital, Manchester). Not funded by the NHS
<b>Torisel</b> <i>Pfizer</i>	Temsirolimus	<b>Targeted therapy:</b> mTOR inhibitor Oral medication	First-line treatment for advanced RCC of poor prognosis	Not routinely available on the NHS Access via individual funding request*
<b>Avastin</b> <i>Roche</i>	Bevacizumab	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Infusion	First-line treatment for advanced/metastatic RCC in combination with interferon alpha	Not routinely available on the NHS Access via individual funding request*
<b>Nexavar</b> <i>Bayer</i>	Sorafenib	<b>Targeted therapy:</b> VEGF tyrosine kinase inhibitor (TKI) Oral medication	First/second-line treatment for advanced/metastatic RCC	Not routinely available on the NHS Access via individual funding request*
<b>Tecentriq plus Avastin</b> <i>Roche</i>	Atezolizumab in combination with bevacizumab	<b>Immunotherapy plus targeted therapy:</b> Anti-PD-L1 checkpoint inhibitor plus	First-line treatment for locally advanced/metastatic RCC	Appraisal suspended

		VEGF tyrosine kinase inhibitor (TKI) Infusion		
<b>Xgeva</b> <i>Amgen</i>	Denosumab	<b>Immunotherapy:</b> RANK ligand inhibitor Injection	Cancer that has spread to the bones as an alternative to bisphosphonates	Available on the NHS

**Clinical Trials for Kidney Cancer - Please go to our clinical trials database for a complete list of all clinical trials for kidney cancer in the UK:**  
<http://www.kcsn.org.uk/clinical-trials-hub/clinical-trials-database/>

\*Individual funding requests may be submitted via the following route:

- England and Northern Ireland: Individual Funding Request (IFR)
- Wales: Individual Patient Funding Request (IPFR)
- Scotland: Individual Patient Treatment Request (IPTR)